CORT
Corcept Therapeutics Incorporated
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2004-04-15
$81.93
+1.47 (+1.83%)
last quote
Want the full multi-source brief on CORT?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$81.93
High
$84.19
Low
$80.92
Previous close
$80.46
Fundamentals
Market cap
$8.98B
P/E (TTM)
162.75x
P/S (TTM)
10.81x
P/B
11.40x
Gross margin
98.30%
Operating margin
0.77%
Net margin
6.64%
Rev growth (YoY)
16.02%
EPS growth (YoY)
-62.50%
ROE
8.41%
52W high
$126.38
52W low
$28.66
Beta
0.61x
Industry peers
by market cap
Recent SEC filings
CIK 1088856filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 11h
Corcept Therapeutics Q3 Earnings Call Highlights
Corcept Therapeutics (NASDAQ:CORT) reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the launch of ovarian cancer treatment Lifyorli lifted results. Net income totaled $126.8 million, compare
ChartMill · 12h
Corcept Therapeutics (NASDAQ:CORT) Q3 EPS Beat Offset by In-Line Revenue and Reiterated Guidance
Corcept Q3 revenue was in line and EPS beat estimates; 2026 guidance was reiterated, but shares fell as investors weighed the neutral top line.
Yahoo · 13h
Corcept Therapeutics falls on guidance despite earnings beat
Investing.com -- Corcept Therapeutics Incorporated (NASDAQ:CORT) reported third-quarter results that exceeded analyst expectations, though shares fell 3.9% in after-hours trading Tuesday as the company's reiterated full-year guidance disappointed investors.
Yahoo · 14h
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
Corcept (CORT) delivered earnings and revenue surprises of +48.53% and +3.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · 14h
Corcept’s (NASDAQ:CORT) Q3 2026: beats on revenue
Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 64% year on year to $340.5 million. The company expects the full year’s revenue to be around $1.15 billion, close to analysts’ consensus estimates. Its GAAP profit of $1.01 per share was 27.2% above analysts’ consensus estimates.
Yahoo · 14h
Corcept: Q3 Earnings Snapshot
(AP) — Corcept Therapeutics Inc. (CORT) on Tuesday reported third-quarter earnings of $124.
Yahoo · 14h
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., November 03, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the third quarter.
SeekingAlpha · 16h
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call November 3, 2026 5:00 PM ESTCompany ParticipantsAtabak Mokari - CFO & TreasurerJustin...
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial